Operational Readiness for Europe: PV, QA and MAH Requirements Biotechs Cannot Ignore

Pharmacovigilance Infrastructure: Establishing EU Safety Oversight

One of the first operational pillars required for European market entry is the establishment of a compliant pharmacovigilance (PV) system.

EU legislation requires every Marketing Authorisation Holder to maintain a pharmacovigilance system capable of continuously monitoring the safety of its medicinal products. This system must support the detection, assessment, and reporting of adverse events throughout the product lifecycle.

Central to this framework is the EU Qualified Person for Pharmacovigilance (EU QPPV).

The EU QPPV is responsible for oversight of the pharmacovigilance system and must reside and operate within the European Union. This individual serves as the primary regulatory contact for safety matters.

However, appointing a QPPV alone is not sufficient. The broader PV infrastructure must also be fully operational.

Typical building blocks include:

• a documented Pharmacovigilance System Master File (PSMF)
• processes for adverse event collection and reporting
• formal signal detection and safety evaluation procedures
• defined governance structures for PV oversight

For companies accustomed to the US regulatory system, establishing this infrastructure often represents a significant organisational expansion.

For products authorised in the United Kingdom, comparable pharmacovigilance obligations apply. Companies must appoint a UK QPPV and ensure that national safety reporting requirements aligned with MHRA guidance are fulfilled.

Quality Governance: Meeting EU Regulatory Expectations

Operational readiness for Europe also requires strong quality governance aligned with EU Good Manufacturing Practice (GMP).

While FDA-regulated systems may already include robust quality processes, the European regulatory environment places additional emphasis on structured oversight and documented accountability.

Quality systems supporting EU market entry must typically ensure:

• oversight of manufacturing and supply chains
• deviation management and investigation processes
• Corrective and Preventive Actions (CAPA)
• change control across the product lifecycle
• documented processes supporting inspection readiness

Inspection readiness is particularly important in the European system. Regulatory authorities expect companies to maintain traceable regulatory decision-making processes across quality, safety, and regulatory domains.

Within the EU framework, this also includes Qualified Person (QP) certification for batch release before products can be placed on the market.

This requires close alignment between internal teams and external partners involved in manufacturing, quality control, and supply chain operations.

The Role of the Marketing Authorisation Holder (MAH)

Under EU legislation, the Marketing Authorisation Holder carries full legal responsibility for the medicinal product placed on the market.

This responsibility extends well beyond the submission phase and covers the entire lifecycle of the product.

The MAH is accountable for ensuring:

• pharmacovigilance oversight
• product quality and regulatory compliance
• lifecycle regulatory management
• communication with European regulatory authorities

For companies entering the EU market, defining the MAH operating model early is essential.

Some organisations establish a European affiliate to assume the MAH role, while others rely on specialised regulatory partners to support operational execution.

In addition, geographical regulatory requirements differ between the EU and the United Kingdom.

For EU-authorised products, the MAH must be established within the European Economic Area (EEA). For UK-authorised products, the MAH must be based in the United Kingdom and interact directly with the MHRA.

For US biotechs planning parallel EU and UK submissions, defining the MAH structure early is therefore essential to avoid delays during market entry.

Regardless of the chosen structure, regulators expect the MAH to maintain clear oversight and accountability for the product.

Key Operational Differences Between EU and UK Market Entry

Although EU and UK regulatory frameworks share many principles, companies preparing for European market entry must account for several structural differences between the two systems.

Following Brexit, the European Union and the United Kingdom operate under separate regulatory authorities and legal frameworks. As a result, certain operational requirements must be addressed independently.

For biotechs planning parallel submissions, the most relevant operational distinctions typically include:

Area	European Union	United Kingdom
Regulatory authority	European Medicines Agency (EMA) and national authorities	Medicines and Healthcare products Regulatory Agency (MHRA)
Marketing Authorisation Holder (MAH)	Must be established in the European Economic Area (EEA)	Must be established in the United Kingdom
Pharmacovigilance	EU QPPV responsible for PV system oversight	UK QPPV required for UK-authorised products
Safety reporting	EudraVigilance system	UK national reporting aligned with MHRA guidance
Batch release	EU Qualified Person (QP) certification required before market release	UK QP certification required for UK supply

While many operational processes remain similar, these structural differences mean that companies must ensure their PV systems, MAH structures, and quality governance models can support both regulatory environments when required.

For US biotechs entering Europe for the first time, addressing these differences early helps prevent delays during regulatory review and product launch preparation.

Aligning PV, QA and Regulatory Functions

A common challenge for companies expanding into Europe is the coordination of responsibilities across pharmacovigilance, quality, and regulatory functions.

Each of these domains operates under distinct regulatory requirements but must function as part of a unified governance framework.

Operational readiness, therefore, requires:

• clear ownership of PV, QA, and regulatory responsibilities
• aligned internal procedures across functions
• effective oversight of external partners and service providers

Without this coordination, operational gaps can emerge that increase regulatory risk after market entry.

Establishing governance frameworks early allows companies to ensure that responsibilities remain aligned as the product moves from approval to commercialisation.

Preparing for Inspections and Lifecycle Responsibilities

European market entry introduces ongoing regulatory oversight.

Companies must remain prepared for inspections related to pharmacovigilance systems, quality governance, and regulatory compliance.

Authorities expect companies to maintain:

• documented pharmacovigilance systems
• robust quality management structures
• traceable regulatory and quality decisions

Operational readiness, therefore, becomes a continuous activity rather than a one-time preparation before launch.

Companies that integrate regulatory expectations into their operating model early are significantly better positioned to maintain compliance throughout the product lifecycle.

Operational Infrastructure Defines Sustainable EU and UK Market Entry

For biotech companies entering Europe, regulatory approval should not be seen as the final milestone.

Instead, it marks the transition into a new phase of operational responsibility.

Pharmacovigilance infrastructure, quality governance, and MAH accountability form the foundation of sustainable compliance within the European regulatory system.

Companies that invest early in these operational structures are better positioned to manage regulatory expectations, respond to authority questions, and maintain compliance throughout the lifecycle of their products.

Strengthening Your Operational Readiness for Europe

Establishing operational readiness for Europe requires coordination across regulatory, pharmacovigilance, and quality domains.

QbD Group supports pharmaceutical and biotech companies in:

• establishing EU pharmacovigilance systems and QPPV structures
• strengthening quality governance frameworks aligned with EU GMP
• defining MAH operating models for EU and UK market entry
• ensuring inspection readiness across PV, QA and regulatory domains

→ Talk to a regulatory expert

References

EMA. Guideline on good pharmacovigilance practices (GVP) https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices

EMA. Marketing Authorisation Holder responsibilities https://www.ema.europa.eu/en/human-regulatory/post-authorisation

EMA. EudraLex Volume 4 – EU Guidelines for GMP https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

MHRA. Pharmacovigilance obligations for marketing authorisation holders https://www.gov.uk/guidance/pharmacovigilance

MHRA. Good manufacturing practice and batch release https://www.gov.uk/guidance/good-manufacturing-practice-and-good-distribution-practice

Planning EU and UK expansion?

Build a robust, Europe-ready strategy across regulatory pathway, clinical planning, and operational setup with QbD's integrated biotech expertise. Ready to align your EU and UK roadmap? Partner with our expansion specialists.

Talk to an expert